Uveal melanoma is the most common primary intraocular malignancy in adults, arising from melanocytes of the uveal tract (iris, ciliary body, and choroid). Unlike cutaneous melanoma, uveal melanoma is characterized by distinct driver mutations, with GNAQ or GNA11 mutations present in approximately 85% of cases, activating the Gq/11-PKC-MAPK signaling axis. BAP1 mutations are the most significant prognostic factor, associated with metastatic disease. Uveal melanoma has a propensity for hepatic metastasis, with approximately 50% of patients eventually developing liver metastases despite successful treatment of the primary tumor. Tebentafusp, a bispecific T-cell engager targeting gp100, represents the first systemic therapy to improve overall survival in metastatic uveal melanoma.
Ask a research question about Uveal Melanoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Uveal Melanoma
creation_date: '2026-01-26T02:55:13Z'
updated_date: '2026-04-22T20:13:21Z'
description: >-
Uveal melanoma is the most common primary intraocular malignancy in adults,
arising from melanocytes of the uveal tract (iris, ciliary body, and choroid).
Unlike cutaneous melanoma, uveal melanoma is characterized by distinct driver
mutations, with GNAQ or GNA11 mutations present in approximately 85% of cases,
activating the Gq/11-PKC-MAPK signaling axis. BAP1 mutations are the most
significant prognostic factor, associated with metastatic disease. Uveal
melanoma has a propensity for hepatic metastasis, with approximately 50% of
patients eventually developing liver metastases despite successful treatment
of the primary tumor. Tebentafusp, a bispecific T-cell engager targeting
gp100, represents the first systemic therapy to improve overall survival
in metastatic uveal melanoma.
categories:
- Ocular Malignancy
- Oncogene-Driven Cancer
parents:
- ocular melanoma
has_subtypes:
- name: Choroidal Melanoma
description: >-
Melanoma arising from the choroid, the vascular layer between the retina
and sclera. Most common uveal melanoma subtype (85-90%). May cause retinal
detachment, visual disturbance, or be discovered incidentally.
- name: Ciliary Body Melanoma
description: >-
Melanoma arising from the ciliary body, located behind the iris. Less common
(5-10%) but associated with higher metastatic risk due to delayed detection
and involvement of vascular structures.
- name: Iris Melanoma
description: >-
Melanoma arising from the iris, the colored portion of the eye. Least common
uveal melanoma subtype (3-5%) but often detected earlier due to visible
pigmented lesion. Generally better prognosis.
pathophysiology:
- name: GNAQ/GNA11 Oncogenic Mutations
description: >-
GNAQ and GNA11 encode alpha subunits of heterotrimeric Gq/11 G-proteins.
Mutations at Q209 (most common) or R183 lock the protein in a constitutively
active GTP-bound state, resulting in persistent downstream signaling
through phospholipase C beta, protein kinase C, and ultimately the MAPK
pathway. These mutations are mutually exclusive and early, initiating events.
evidence:
- reference: PMID:23877823
reference_title: "[Uveal melanoma: current insights into clinical relevance of genetic testing]."
supports: PARTIAL
snippet: "Recently, major key genes involved in uveal melanoma development, GNAQ, GNA11, BAP1, SF3B1 and EIF1AX, have been identified."
explanation: "Supports GNAQ and GNA11 as key genes in uveal melanoma development."
cell_types:
- preferred_term: melanocyte
term:
id: CL:0000148
label: melanocyte
biological_processes:
- preferred_term: signal transduction
modifier: INCREASED
term:
id: GO:0007165
label: signal transduction
locations:
- preferred_term: uvea
term:
id: UBERON:0001768
label: uvea
downstream:
- target: PKC-MAPK Pathway Activation
description: Active Gq/11 stimulates PLC-beta, generating DAG to activate PKC
- name: PKC-MAPK Pathway Activation
description: >-
Constitutively active GNAQ/GNA11 signaling activates phospholipase C-beta,
generating diacylglycerol (DAG) that activates protein kinase C (PKC).
PKC in turn activates the RAF-MEK-ERK cascade, driving melanocyte proliferation.
This pathway represents a therapeutic target with MEK and PKC inhibitors.
biological_processes:
- preferred_term: MAPK cascade
modifier: INCREASED
term:
id: GO:0000165
label: MAPK cascade
downstream:
- target: Uncontrolled Uveal Melanocyte Proliferation
description: ERK activation drives cell cycle progression and proliferation
- name: Uncontrolled Uveal Melanocyte Proliferation
description: >-
Persistent MAPK signaling drives proliferation of uveal melanocytes,
leading to tumor formation. Unlike cutaneous melanoma, uveal melanoma
rarely harbors BRAF or NRAS mutations.
cell_types:
- preferred_term: melanocyte
term:
id: CL:0000148
label: melanocyte
locations:
- preferred_term: uvea
term:
id: UBERON:0001768
label: uvea
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
- name: BAP1 Loss and Metastatic Progression
description: >-
BAP1 (BRCA1-associated protein 1) is a tumor suppressor encoding a deubiquitinase
involved in chromatin remodeling and DNA damage response. BAP1 loss occurs in
approximately 40% of uveal melanomas and is strongly associated with metastatic
disease and poor prognosis. BAP1-deficient tumors exhibit altered gene expression
patterns consistent with a more aggressive, less differentiated phenotype.
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
histopathology:
- name: Melanocytic Neoplasm
finding_term:
preferred_term: Melanocytic Neoplasm
term:
id: NCIT:C7058
label: Melanocytic Neoplasm
frequency: VERY_FREQUENT
description: Malignant melanoma represents a neoplasm stemming from melanocytes.
evidence:
- reference: PMID:27268913
reference_title: "Malignant melanoma: diagnosis, treatment and cancer stem cells."
supports: SUPPORT
snippet: "Malignant melanoma represents a neoplasm stemming from melanocytes"
explanation: Abstract defines melanoma as a neoplasm stemming from melanocytes.
phenotypes:
- category: Ocular
name: Uveal Melanoma
frequency: OBLIGATE
diagnostic: true
description: >-
Intraocular melanoma arising from uveal melanocytes. Most commonly presents
in the choroid (85%), with ciliary body and iris involvement less common.
phenotype_term:
preferred_term: Uveal melanoma
term:
id: HP:0007716
label: Uveal melanoma
- category: Ocular
name: Decreased Visual Acuity
frequency: FREQUENT
description: >-
Vision loss occurs when the tumor involves the macula, causes retinal
detachment, or obstructs the visual axis. Many tumors are discovered
incidentally before causing visual symptoms.
phenotype_term:
preferred_term: Reduced visual acuity
term:
id: HP:0007663
label: Reduced visual acuity
- category: Ocular
name: Visual Field Defect
frequency: FREQUENT
description: >-
Visual field defects corresponding to the location of retinal detachment
or tumor position may be the presenting symptom.
phenotype_term:
preferred_term: Visual field defect
term:
id: HP:0001123
label: Visual field defect
genetic:
- name: GNAQ Q209
association: Somatic Oncogenic Mutation
notes: >-
Most common driver mutation in uveal melanoma, occurring in approximately
45% of cases. Q209L and Q209P mutations lock the Gq alpha subunit in active
GTP-bound state by disrupting GTPase activity.
- name: GNA11 Q209
association: Somatic Oncogenic Mutation
notes: >-
Mutually exclusive with GNAQ mutations, present in approximately 40% of
uveal melanomas. Functionally equivalent to GNAQ mutations, resulting in
constitutive G11 alpha subunit activation.
- name: BAP1
association: Somatic Tumor Suppressor Loss
notes: >-
BAP1 loss-of-function mutations occur in approximately 40% of uveal melanomas
and are the strongest predictor of metastatic disease. Germline BAP1 mutations
predispose to uveal melanoma, mesothelioma, and renal cell carcinoma.
- name: SF3B1
association: Somatic Mutation
notes: >-
SF3B1 mutations occur in approximately 15-20% of uveal melanomas and are
associated with intermediate prognosis. SF3B1 encodes a splicing factor,
and mutations cause widespread splicing alterations.
- name: EIF1AX
association: Somatic Mutation
notes: >-
EIF1AX mutations occur in approximately 15-20% of uveal melanomas and are
associated with favorable prognosis and low metastatic risk. Mutually
exclusive with BAP1 mutations.
treatments:
- name: Tebentafusp
description: >-
Bispecific T-cell engager (TCE) that binds gp100 peptide presented by HLA-A*02:01
on tumor cells and CD3 on T cells, redirecting T cells to kill melanoma cells.
First systemic therapy to improve overall survival in metastatic uveal melanoma.
Requires HLA-A*02:01 positive status (approximately 50% of patients).
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
therapeutic_agent:
- preferred_term: tebentafusp
term:
id: NCIT:C94208
label: Tebentafusp
- name: Plaque Brachytherapy
description: >-
Radiation therapy using radioactive plaque sutured to the sclera overlying
the tumor. First-line local therapy for many uveal melanomas, achieving
excellent local control while preserving the eye in most cases.
treatment_term:
preferred_term: brachytherapy
term:
id: MAXO:0000014
label: radiation therapy
qualifiers:
- predicate:
preferred_term: procedure type
term:
id: NCIT:C25187
label: Type
value:
preferred_term: brachytherapy
term:
id: NCIT:C15195
label: Brachytherapy
- name: Enucleation
description: >-
Surgical removal of the eye. Indicated for large tumors, those with optic
nerve involvement, or when vision cannot be preserved. Provides excellent
local control but does not prevent metastatic disease.
treatment_term:
preferred_term: eye enucleation
term:
id: MAXO:0000004
label: surgical procedure
qualifiers:
- predicate:
preferred_term: procedure type
term:
id: NCIT:C25187
label: Type
value:
preferred_term: eye enucleation
term:
id: NCIT:C198837
label: Eye Enucleation
- name: Immune Checkpoint Inhibitors
description: >-
Anti-PD-1 and anti-CTLA-4 antibodies have limited efficacy in uveal melanoma
compared to cutaneous melanoma, with response rates of approximately 5-10%.
The immunologically cold tumor microenvironment may contribute to this
resistance.
treatment_term:
preferred_term: immunotherapy
term:
id: NCIT:C15262
label: Immunotherapy
therapeutic_agent:
- preferred_term: ipilimumab
term:
id: NCIT:C2654
label: Ipilimumab
- preferred_term: nivolumab
term:
id: NCIT:C68814
label: Nivolumab
disease_term:
preferred_term: uveal melanoma
term:
id: MONDO:0006486
label: uveal melanoma
notes: >-
Uveal melanoma is molecularly distinct from cutaneous melanoma, with GNAQ/GNA11
mutations instead of BRAF/NRAS mutations. The propensity for hepatic metastasis
is poorly understood but may relate to unique adhesion molecule expression or
liver tropism factors. Despite excellent local control rates, approximately
50% of patients develop metastatic disease, usually to the liver, with median
survival of less than one year after metastasis. Clinical trials are evaluating
hepatic-directed therapies and novel systemic approaches.
classifications:
icdo_morphology:
classification_value: Melanoma
harrisons_chapter:
- classification_value: cancer
- classification_value: solid tumor
references:
- reference: DOI:10.1007/s00432-021-03851-9
title: Vasculogenic mimicry correlates to presenting symptoms and mortality in uveal melanoma
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Fluid-conducting extracellular matrix patterns known as vasculogenic mimicry (VM) have been associated with poor prognosis in uveal melanoma and other cancers.
supporting_text: Fluid-conducting extracellular matrix patterns known as vasculogenic mimicry (VM) have been associated with poor prognosis in uveal melanoma and other cancers.
evidence:
- reference: DOI:10.1007/s00432-021-03851-9
reference_title: Vasculogenic mimicry correlates to presenting symptoms and mortality in uveal melanoma
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Fluid-conducting extracellular matrix patterns known as vasculogenic mimicry (VM) have been associated with poor prognosis in uveal melanoma and other cancers.
explanation: Deep research cited this publication as relevant literature for Uveal Melanoma.
- reference: DOI:10.1007/s10238-024-01497-8
title: 'Immunotherapy response and resistance in patients with advanced uveal melanoma: a retrospective cohort study'
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Metastatic uveal melanoma (mUM) is associated with poor prognosis.
supporting_text: Metastatic uveal melanoma (mUM) is associated with poor prognosis.
evidence:
- reference: DOI:10.1007/s10238-024-01497-8
reference_title: 'Immunotherapy response and resistance in patients with advanced uveal melanoma: a retrospective cohort study'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Metastatic uveal melanoma (mUM) is associated with poor prognosis.
explanation: Deep research cited this publication as relevant literature for Uveal Melanoma.
- reference: DOI:10.1016/j.esmoop.2025.104496
title: How we treat patients with metastatic uveal melanoma
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: How we treat patients with metastatic uveal melanoma
supporting_text: How we treat patients with metastatic uveal melanoma
- reference: DOI:10.1016/j.ophtha.2020.11.023
title: Presenting Symptoms Are Associated with Uveal Melanoma-Related Death
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Presenting Symptoms Are Associated with Uveal Melanoma-Related Death
supporting_text: Presenting Symptoms Are Associated with Uveal Melanoma-Related Death
- reference: DOI:10.1038/eye.2016.275
title: 'Uveal melanoma: relatively rare but deadly cancer'
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: 'Uveal melanoma: relatively rare but deadly cancer'
supporting_text: 'Uveal melanoma: relatively rare but deadly cancer'
- reference: DOI:10.1038/s41433-024-02959-9
title: Ambient ultraviolet radiation and ocular melanoma incidence in the United States, 2000−2019
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Ocular melanoma is a rare, but deadly cancer.
supporting_text: Ocular melanoma is a rare, but deadly cancer.
evidence:
- reference: DOI:10.1038/s41433-024-02959-9
reference_title: Ambient ultraviolet radiation and ocular melanoma incidence in the United States, 2000−2019
supports: SUPPORT
evidence_source: OTHER
snippet: Ocular melanoma is a rare, but deadly cancer.
explanation: Deep research cited this publication as relevant literature for Uveal Melanoma.
- reference: DOI:10.1038/s41433-024-03035-y
title: Comparing efficacy of charged-particle therapy with brachytherapy in treatment of uveal melanoma
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Comparing efficacy of charged-particle therapy with brachytherapy in treatment of uveal melanoma
supporting_text: Comparing efficacy of charged-particle therapy with brachytherapy in treatment of uveal melanoma
- reference: DOI:10.1038/s41467-024-53145-0
title: Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp
supporting_text: Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp
- reference: DOI:10.1038/s41571-022-00714-1
title: Advances in the clinical management of uveal melanoma
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Advances in the clinical management of uveal melanoma
supporting_text: Advances in the clinical management of uveal melanoma
- reference: DOI:10.1038/s41572-020-0158-0
title: Uveal melanoma
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Uveal melanoma
supporting_text: Uveal melanoma
- reference: DOI:10.1111/pcmr.70041
title: Germline Cancer Susceptibility Variants in Patients With Uveal Melanoma
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: 'Some patients with uveal melanoma (UM) show genetic cancer predisposition: ~2% harbor a pathogenic or likely pathogenic (P/LP) germline variant in BAP1 or, rarely, in 20 other cancer‐associated genes.'
supporting_text: 'Some patients with uveal melanoma (UM) show genetic cancer predisposition: ~2% harbor a pathogenic or likely pathogenic (P/LP) germline variant in BAP1 or, rarely, in 20 other cancer‐associated genes.'
evidence:
- reference: DOI:10.1111/pcmr.70041
reference_title: Germline Cancer Susceptibility Variants in Patients With Uveal Melanoma
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: 'Some patients with uveal melanoma (UM) show genetic cancer predisposition: ~2% harbor a pathogenic or likely pathogenic (P/LP) germline variant in BAP1 or, rarely, in 20 other cancer‐associated genes.'
explanation: Deep research cited this publication as relevant literature for Uveal Melanoma.
- reference: DOI:10.1136/jitc-2024-009028
title: Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
supporting_text: Tebentafusp, a bispecific (gp100×CD3) ImmTAC, significantly improved overall survival (OS) outcomes for HLA-A*02:01+ adult patients with untreated metastatic uveal melanoma (mUM) and showed promising survival in previously treated mUM with 1-year OS of 62% in the primary analysis of study IMCgp100-102.
evidence:
- reference: DOI:10.1136/jitc-2024-009028
reference_title: Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Tebentafusp, a bispecific (gp100×CD3) ImmTAC, significantly improved overall survival (OS) outcomes for HLA-A*02:01+ adult patients with untreated metastatic uveal melanoma (mUM) and showed promising survival in previously treated mUM with 1-year OS of 62% in the primary analysis of study IMCgp100-102.
explanation: Deep research cited this publication as relevant literature for Uveal Melanoma.
- reference: DOI:10.1159/000543151
title: 'Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1975–2020)'
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Since 2003, using the Surveillance, Epidemiology, and End Results (SEER) database, epidemiological aspects of uveal melanoma have been reported.
supporting_text: Since 2003, using the Surveillance, Epidemiology, and End Results (SEER) database, epidemiological aspects of uveal melanoma have been reported.
evidence:
- reference: DOI:10.1159/000543151
reference_title: 'Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1975–2020)'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Since 2003, using the Surveillance, Epidemiology, and End Results (SEER) database, epidemiological aspects of uveal melanoma have been reported.
explanation: Deep research cited this publication as relevant literature for Uveal Melanoma.
- reference: DOI:10.1177/15330338251343144
title: 'Percutaneous Locoregional Therapies for the Treatment of Liver Metastases from Uveal Melanoma: A Systematic Review'
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: The prognosis of patients with uveal melanoma is related to several factors, including local or extraocular extension of the disease.
supporting_text: The prognosis of patients with uveal melanoma is related to several factors, including local or extraocular extension of the disease.
evidence:
- reference: DOI:10.1177/15330338251343144
reference_title: 'Percutaneous Locoregional Therapies for the Treatment of Liver Metastases from Uveal Melanoma: A Systematic Review'
supports: SUPPORT
evidence_source: OTHER
snippet: The prognosis of patients with uveal melanoma is related to several factors, including local or extraocular extension of the disease.
explanation: Deep research cited this publication as relevant literature for Uveal Melanoma.
- reference: DOI:10.1186/s13014-024-02580-w
title: 'Efficacy and safety of proton radiotherapy in treating choroidal melanoma: a systematic review and meta-analysis'
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: 'Efficacy and safety of proton radiotherapy in treating choroidal melanoma: a systematic review and meta-analysis'
supporting_text: 'Efficacy and safety of proton radiotherapy in treating choroidal melanoma: a systematic review and meta-analysis'
- reference: DOI:10.1200/jco.24.00447
title: '15-Gene Expression Profile and <i>PRAME</i> as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1)'
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Validated and accurate prognostic testing is critical for precision medicine in uveal melanoma (UM).
supporting_text: Validated and accurate prognostic testing is critical for precision medicine in uveal melanoma (UM).
evidence:
- reference: DOI:10.1200/jco.24.00447
reference_title: '15-Gene Expression Profile and <i>PRAME</i> as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1)'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Validated and accurate prognostic testing is critical for precision medicine in uveal melanoma (UM).
explanation: Deep research cited this publication as relevant literature for Uveal Melanoma.
- reference: DOI:10.12775/qs.2024.23.55123
title: What Sets Uveal Melanoma Apart, and How Can We Address It? A Comprehensive Review of Pathophysiology, Diagnosis and Treatment
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Uveal melanoma (UM) is a serious condition requiring immediate medical attention.
supporting_text: Uveal melanoma (UM) is a serious condition requiring immediate medical attention.
evidence:
- reference: DOI:10.12775/qs.2024.23.55123
reference_title: What Sets Uveal Melanoma Apart, and How Can We Address It? A Comprehensive Review of Pathophysiology, Diagnosis and Treatment
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Uveal melanoma (UM) is a serious condition requiring immediate medical attention.
explanation: Deep research cited this publication as relevant literature for Uveal Melanoma.
- reference: DOI:10.1371/journal.pone.0306386
title: Characterization of somatic mutations in sporadic uveal melanoma and uveal melanoma in patients with germline BAP1 pathogenic variants
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Genetic analyses were conducted on tumor samples from 88 patients with uveal melanoma (UM), 6 of whom carry pathogenic germline variants in BAP1.
supporting_text: Genetic analyses were conducted on tumor samples from 88 patients with uveal melanoma (UM), 6 of whom carry pathogenic germline variants in BAP1.
evidence:
- reference: DOI:10.1371/journal.pone.0306386
reference_title: Characterization of somatic mutations in sporadic uveal melanoma and uveal melanoma in patients with germline BAP1 pathogenic variants
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Genetic analyses were conducted on tumor samples from 88 patients with uveal melanoma (UM), 6 of whom carry pathogenic germline variants in BAP1.
explanation: Deep research cited this publication as relevant literature for Uveal Melanoma.
- reference: DOI:10.21873/invivo.13633
title: Iodine Plaque Brachytherapy a Customized Conservative Approach to the Management of Medium/Large-sized Uveal Melanoma
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Iodine Plaque Brachytherapy a Customized Conservative Approach to the Management of Medium/Large-sized Uveal Melanoma
supporting_text: Iodine Plaque Brachytherapy a Customized Conservative Approach to the Management of Medium/Large-sized Uveal Melanoma
- reference: DOI:10.32604/or.2025.071831
title: 'Clinical Molecular Pathology and Treatment Developments in Advanced Uveal Melanoma: State of the Art'
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: 'Clinical Molecular Pathology and Treatment Developments in Advanced Uveal Melanoma: State of the Art'
supporting_text: 'Clinical Molecular Pathology and Treatment Developments in Advanced Uveal Melanoma: State of the Art'
- reference: DOI:10.3389/fonc.2025.1667282
title: 'Evaluating the efficacy and safety of tebentafusp in the treatment of metastatic uveal melanoma: a 2025 update systematic review and meta-analysis'
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Metastatic uveal melanoma (mUM) is an aggressive malignancy with a dismal prognosis, posing a severe threat to patients’ survival and quality of life.
supporting_text: Metastatic uveal melanoma (mUM) is an aggressive malignancy with a dismal prognosis, posing a severe threat to patients’ survival and quality of life.
evidence:
- reference: DOI:10.3389/fonc.2025.1667282
reference_title: 'Evaluating the efficacy and safety of tebentafusp in the treatment of metastatic uveal melanoma: a 2025 update systematic review and meta-analysis'
supports: SUPPORT
evidence_source: OTHER
snippet: Metastatic uveal melanoma (mUM) is an aggressive malignancy with a dismal prognosis, posing a severe threat to patients’ survival and quality of life.
explanation: Deep research cited this publication as relevant literature for Uveal Melanoma.
- reference: DOI:10.3390/cancers16050931
title: 'Incidence and Mortality of Uveal Melanoma in Hungary: A Nationwide Study'
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Uveal melanoma (UM) is the most common primary malignant ocular tumour in adults, although its epidemiology in Central and Eastern Europe is unclear.
supporting_text: Uveal melanoma (UM) is the most common primary malignant ocular tumour in adults, although its epidemiology in Central and Eastern Europe is unclear.
evidence:
- reference: DOI:10.3390/cancers16050931
reference_title: 'Incidence and Mortality of Uveal Melanoma in Hungary: A Nationwide Study'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Uveal melanoma (UM) is the most common primary malignant ocular tumour in adults, although its epidemiology in Central and Eastern Europe is unclear.
explanation: Deep research cited this publication as relevant literature for Uveal Melanoma.
- reference: DOI:10.3390/cancers16051074
title: Current and Emerging Radiotherapy Options for Uveal Melanoma
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: What treatment options are there for patients having uveal melanoma?
supporting_text: What treatment options are there for patients having uveal melanoma?
evidence:
- reference: DOI:10.3390/cancers16051074
reference_title: Current and Emerging Radiotherapy Options for Uveal Melanoma
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: What treatment options are there for patients having uveal melanoma?
explanation: Deep research cited this publication as relevant literature for Uveal Melanoma.
- reference: DOI:10.3390/cancers16142510
title: 'Impact of Driver Mutations on Metastasis-Free Survival in Uveal Melanoma: A Meta-Analysis'
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: The prognosis of uveal melanoma is significantly influenced by the risk of metastasis, which varies according to clinical and genetic features.
supporting_text: The prognosis of uveal melanoma is significantly influenced by the risk of metastasis, which varies according to clinical and genetic features.
evidence:
- reference: DOI:10.3390/cancers16142510
reference_title: 'Impact of Driver Mutations on Metastasis-Free Survival in Uveal Melanoma: A Meta-Analysis'
supports: SUPPORT
evidence_source: OTHER
snippet: The prognosis of uveal melanoma is significantly influenced by the risk of metastasis, which varies according to clinical and genetic features.
explanation: Deep research cited this publication as relevant literature for Uveal Melanoma.
- reference: DOI:10.3390/cancers16203497
title: Proton Therapy in Uveal Melanoma
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Uveal melanoma is the most common primary intraocular malignancy in adults.
supporting_text: Uveal melanoma is the most common primary intraocular malignancy in adults.
evidence:
- reference: DOI:10.3390/cancers16203497
reference_title: Proton Therapy in Uveal Melanoma
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Uveal melanoma is the most common primary intraocular malignancy in adults.
explanation: Deep research cited this publication as relevant literature for Uveal Melanoma.
- reference: DOI:10.3390/cancers18010121
title: 'Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus'
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Uveal melanoma is a rare but aggressive intraocular malignancy that metastasizes in up to half of patients, most commonly to the liver, despite effective local treatment.
supporting_text: Uveal melanoma is a rare but aggressive intraocular malignancy that metastasizes in up to half of patients, most commonly to the liver, despite effective local treatment.
evidence:
- reference: DOI:10.3390/cancers18010121
reference_title: 'Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus'
supports: SUPPORT
evidence_source: OTHER
snippet: Uveal melanoma is a rare but aggressive intraocular malignancy that metastasizes in up to half of patients, most commonly to the liver, despite effective local treatment.
explanation: Deep research cited this publication as relevant literature for Uveal Melanoma.
- reference: DOI:10.3390/cimb48020131
title: 'Precision Oncology in Ocular Melanoma: Integrating Molecular and Liquid Biopsy Biomarkers'
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Ocular melanomas, comprising uveal melanoma (UM) and conjunctival melanoma (CoM), represent the most common primary intraocular and ocular surface malignancies in adults.
supporting_text: Ocular melanomas, comprising uveal melanoma (UM) and conjunctival melanoma (CoM), represent the most common primary intraocular and ocular surface malignancies in adults.
evidence:
- reference: DOI:10.3390/cimb48020131
reference_title: 'Precision Oncology in Ocular Melanoma: Integrating Molecular and Liquid Biopsy Biomarkers'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Ocular melanomas, comprising uveal melanoma (UM) and conjunctival melanoma (CoM), represent the most common primary intraocular and ocular surface malignancies in adults.
explanation: Deep research cited this publication as relevant literature for Uveal Melanoma.
- reference: DOI:10.3390/diagnostics14090958
title: Pathological and Molecular Diagnosis of Uveal Melanoma
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: (1) Uveal melanoma (UM) is a common malignant intraocular tumor that presents with significant genetic differences to cutaneous melanoma and has a high genetic burden in terms of prognosis.
supporting_text: (1) Uveal melanoma (UM) is a common malignant intraocular tumor that presents with significant genetic differences to cutaneous melanoma and has a high genetic burden in terms of prognosis.
evidence:
- reference: DOI:10.3390/diagnostics14090958
reference_title: Pathological and Molecular Diagnosis of Uveal Melanoma
supports: SUPPORT
evidence_source: OTHER
snippet: (1) Uveal melanoma (UM) is a common malignant intraocular tumor that presents with significant genetic differences to cutaneous melanoma and has a high genetic burden in terms of prognosis.
explanation: Deep research cited this publication as relevant literature for Uveal Melanoma.
- reference: DOI:10.3390/ijms26199799
title: 'Ocular Melanoma: A Comprehensive Review with a Focus on Molecular Biology'
found_in:
- Uveal_Melanoma-deep-research-falcon.md
findings:
- statement: Ocular melanoma is a rare but clinically significant malignancy, primarily comprising uveal and conjunctival subtypes.
supporting_text: Ocular melanoma is a rare but clinically significant malignancy, primarily comprising uveal and conjunctival subtypes.
evidence:
- reference: DOI:10.3390/ijms26199799
reference_title: 'Ocular Melanoma: A Comprehensive Review with a Focus on Molecular Biology'
supports: SUPPORT
evidence_source: OTHER
snippet: Ocular melanoma is a rare but clinically significant malignancy, primarily comprising uveal and conjunctival subtypes.
explanation: Deep research cited this publication as relevant literature for Uveal Melanoma.
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Please provide a comprehensive research report on Uveal Melanoma covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.
For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.
Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed
Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Search first: CTD, PubMed, PheGenI, GxE databases
Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC
For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype
Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser
Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Search first: CDC databases, WHO, PubMed, NHANES
Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON
Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Search first: PubMed, Gene Ontology, Reactome
Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types
Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Search first: OMIM, Orphanet, HPO, PubMed
Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.
Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Search first: NSGC resources, ACMG guidelines, GeneReviews
Search first: Clinical guidelines, FDA approvals, PubMed
Search first: NCBI Taxonomy
Search first: VBO (Vertebrate Breed Ontology)
Search first: NCBI Gene
Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease
This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details
Disease overview and definition. Uveal melanoma (UM) is a malignant neoplasm arising from melanocytes in the uveal tract (iris, ciliary body, choroid) and is the most common primary malignant intraocular tumor in adults. (pasarica2024pathologicalandmolecular pages 1-2, NCT07063875 chunk 1)
Category. Rare ocular cancer (melanoma subtype); primary intraocular malignancy. (pasarica2024pathologicalandmolecular pages 1-2, NCT07063875 chunk 1)
Key identifiers (available in current evidence corpus). - MeSH preferred term: Uveal Melanoma; MeSH ID: D000098943 (as listed in ClinicalTrials.gov MeSH tagging). (NCT07063875 chunk 1) - ICD-O site codes used in SEER registry studies: C69.3 (choroid); C69.4 (ciliary body and iris); melanoma morphology codes 8720–8790 were used to identify melanoma histologies. (weinberger2025uvealmelanoma5year pages 1-2) - AJCC staging: AJCC 8th edition TNM staging is the current standard for iris and posterior uveal melanoma. (pasarica2024pathologicalandmolecular pages 2-4)
Identifiers not retrievable from current tool corpus. MONDO ID, Orphanet ID, and OMIM disease entries were not available in the retrieved documents; therefore they cannot be asserted here without external ontology lookup.
Common synonyms / alternative names (used in the evidence corpus). - Ocular melanoma (when referring broadly to intraocular melanoma subtypes) (lissak2024whatsetsuveal pages 1-3) - Posterior uveal melanoma (commonly meaning choroid/ciliary body) (pasarica2024pathologicalandmolecular pages 2-4)
Data provenance (EHR vs aggregated resources). Most epidemiology and outcomes statistics cited here derive from aggregated registry resources (e.g., SEER; national insurance databases) and multi-center cohorts, rather than single-institution EHR alone. (weinberger2025uvealmelanoma5year pages 2-4, toth2024incidenceandmortality pages 1-2)
UM is biologically distinct from cutaneous melanoma and is characterized by: (i) a small number of recurrent initiating driver mutations (GNAQ/GNA11 axis), (ii) strong prognostic dependence on secondary alterations (e.g., BAP1 loss, monosomy 3), and (iii) marked hepatotropism, with the liver being the predominant metastatic site. (pasarica2024pathologicalandmolecular pages 1-2, iavarone2025ocularmelanomaa pages 4-6)
Recent reviews emphasize that effective local control of the primary tumor has not translated into major improvements in population-level survival, largely because micrometastatic disease is often present at diagnosis and metastasis can occur years later. (pasarica2024pathologicalandmolecular pages 1-2, weinberger2025uvealmelanoma5year pages 1-2)
Somatic oncogenesis. UM tumorigenesis is typically initiated by mutually exclusive activating mutations in GNAQ or GNA11 (and less commonly PLCB4 or CYSLTR2), with secondary alterations (BAP1 inactivation; SF3B1; EIF1AX) shaping metastatic risk. (pasarica2024pathologicalandmolecular pages 1-2, iavarone2025ocularmelanomaa pages 4-6)
Phenotype and ancestry. Registry and review data consistently indicate increased UM incidence among people with light pigmentation phenotypes (e.g., light eye color, sun-sensitive skin) and strong predominance in White populations in US registries (≈98% White in SEER-based analyses). (weinberger2025uvealmelanoma5year pages 2-4, jager2020uvealmelanoma pages 2-3)
Ultraviolet radiation (UVR): subsite-specific associations (2024 registry analysis). A large US registry study linking satellite-based ambient UVR to ocular melanoma incidence (2000–2019) found no association with total ocular melanoma overall, but observed increased incidence for ciliary body/iris melanoma in the highest UVR quartile and reduced incidence for choroidal melanoma in that quartile (Q4 vs Q1 IRR 1.63 for ciliary body/iris; IRR 0.86 for choroid). (arockiaraj2024ambientultravioletradiation pages 1-2)
Germline predisposition. Germline susceptibility is uncommon but clinically important. A 2025 high-risk sequencing study summarized that BAP1 is the only known high-penetrance UM susceptibility gene, with pathogenic/likely pathogenic germline BAP1 variants estimated at ~2% of all UM and up to ~25% of familial UM; 1–4% of cases are reported as familial. (repo2025germlinecancersusceptibility pages 1-3)
Germline BAP1 and outcomes. In a 2024 cohort that included six germline BAP1 carriers, 5/6 developed metastases, consistent with high metastatic risk in this subgroup. (wadt2024characterizationofsomatic pages 1-2)
No protective genetic or environmental factors with quantitative effect estimates were available in the retrieved evidence corpus.
Evidence in this corpus supports a plausible interaction between pigmentation genetics/phenotype and ocular environmental exposures (including light exposure), but does not provide definitive causal interaction models. For example, risk is linked to pigmentation-associated loci (e.g., HERC2/OCA2) and UVR associations appear subsite-dependent (iris/ciliary body vs choroid). (jager2020uvealmelanoma pages 2-3, arockiaraj2024ambientultravioletradiation pages 1-2)
Large clinical cohorts show that UM can be asymptomatic or present with nonspecific visual symptoms.
Posterior UM cohort (n=1,449): - Blurred vision: 39% (559/1,449) - Visual field defect (“shadow”): 16% (277/1,449) - Photopsia and/or floaters: 12% (176/1,449) - Asymptomatic: 28% (400/1,449) - Retinal detachment (recorded subset): 63% (245/391) with exudative detachments among those with recorded RD status - Mean symptom duration: 4 months (SD 5) (fili2021presentingsymptomsare pages 1-2)
Enucleation cohort (n=69): blurred vision 49%, visual field shadow 26%, photopsia/floaters 10%, no symptoms 13%. (sabazade2022vasculogenicmimicrycorrelates pages 1-3)
Classic symptom profile in a high-citation review: blurred vision 38%, photopsia 9%, floaters 7%, visual field loss 6%, ~30% asymptomatic. (kaliki2017uvealmelanomarelatively pages 4-6)
Suggested HPO mappings (not exhaustive; terms named for KB usability): - Blurred vision → HP:0000622 (Blurred vision) (supported by cohort symptom data). (fili2021presentingsymptomsare pages 1-2) - Visual field defect/shadow → HP:0001129 (Visual field defect). (fili2021presentingsymptomsare pages 1-2) - Photopsia → HP:0001100 (Photopsia). (fili2021presentingsymptomsare pages 1-2) - Floaters → HP:0000628 (Vitreous floaters). (fili2021presentingsymptomsare pages 1-2) - Metamorphopsia/distorted vision → HP:0000570 (Metamorphopsia). (fili2021presentingsymptomsare pages 1-2) - Exudative retinal detachment → HP:0000541 (Retinal detachment) (subtype not explicitly coded in HPO; record as RD and add free-text qualifier). (fili2021presentingsymptomsare pages 1-2)
UM is typically diagnosed in older adults; SEER data show a median age at diagnosis around 63 years. (weinberger2025uvealmelanoma5year pages 1-2)
Vision-related QoL impact is substantial because initial symptoms and treatment toxicities commonly involve visual acuity decline and retinal complications, particularly after radiotherapy. (semeniuk2024currentandemerging pages 2-3)
UM is characterized by (i) early initiating oncogenic mutations and (ii) secondary progression alterations with strong prognostic significance. A 2024 diagnostics review states: early/initiating mutations include GNAQ, GNA11, PLCB4, CYSLTR2; secondary progression alterations include BAP1 inactivation and SF3B1/EIF1AX mutations. (pasarica2024pathologicalandmolecular pages 1-2)
A mechanistic review describes Gαq/Gα11 signaling as a central upstream axis that feeds into PLCβ→PKC→MAPK, PI3K/AKT/mTOR, and YAP/TAZ transcriptional programs. (iavarone2025ocularmelanomaa pages 4-6)
A commonly used genomic stratification scheme (TCGA-based) emphasizes chromosome 3 and 8q copy-number status, yielding risk classes with distinct metastasis rates; one validation study reported 5-year cumulative distant metastasis rates: 4% (class A), 20% (B), 33% (C), 63% (D). (pasarica2024pathologicalandmolecular pages 1-2, pasarica2024pathologicalandmolecular pages 9-10)
Structured summary artifact. The table below summarizes initiating vs progression drivers, approximate frequencies where available, and prognostic associations.
| Category | Gene/Alteration | Approx. frequency/range (reported) | Key pathway/mechanism | Prognostic association | Key supporting citation IDs |
|---|---|---|---|---|---|
| Initiating | GNAQ hotspot mutation (Q209, less often R183) | ~45–55%; ~45% in some summaries | Constitutive Gαq activation; PLCβ→PKC→MAPK/ERK, PI3K/AKT/mTOR, TRIO/RhoA→YAP/TAZ | Early oncogenic driver; not independently linked to markedly increased metastatic risk in meta-analysis | (ambrosio2026amultifacetedapproach pages 9-12, kastelan2026precisiononcologyin pages 4-5, dore2026clinicalmolecularpathology pages 3-5, lamasfrancis2024impactofdriver pages 1-2) |
| Initiating | GNA11 hotspot mutation (Q209, less often R183) | ~30–40%; ~42% in some summaries | Same Gαq-driven signaling as GNAQ; constitutive PLCβ/PKC/MAPK and YAP/TAZ activation | Early driver; associated in some reports with shorter disease-specific survival and more high-risk cytogenetics than GNAQ | (ambrosio2026amultifacetedapproach pages 9-12, kastelan2026precisiononcologyin pages 4-5, dore2026clinicalmolecularpathology pages 3-5) |
| Initiating | PLCB4 activating mutation | ~3–4% (rare; 1–5% in some reviews) | Downstream effector of Gαq; activates PKC and convergent MAPK signaling | Rare initiating event; mainly biologically convergent with GNAQ/GNA11 rather than independently prognostic | (pasarica2024pathologicalandmolecular pages 1-2, kastelan2026precisiononcologyin pages 4-5, dore2026clinicalmolecularpathology pages 3-5) |
| Initiating | CYSLTR2 activating mutation (e.g., p.L129Q) | ~2–4% (rare; 1–5% in some reviews) | GPCR upstream of Gαq; produces GNAQ-like signaling | Rare initiating event; prognostic effect less established than secondary alterations | (pasarica2024pathologicalandmolecular pages 1-2, kastelan2026precisiononcologyin pages 4-5, dore2026clinicalmolecularpathology pages 3-5) |
| Progression | BAP1 loss/inactivation (often with monosomy 3) | ~40–45%; ~1/3 in some summaries; 47% in one review; 84% of metastatic UM in one review | Tumor suppressor loss; chromatin regulation/deubiquitination defects, dedifferentiation, metastatic phenotype, altered methylation state | Strongest adverse molecular marker; significantly increases metastasis risk; associated with early metastasis and poor survival | (iavarone2025ocularmelanomaa pages 4-6, kastelan2026precisiononcologyin pages 4-5, dore2026clinicalmolecularpathology pages 3-5, lamasfrancis2024impactofdriver pages 1-2, wadt2024characterizationofsomatic pages 1-2) |
| Progression | Monosomy 3 | ~45–50% | Cytogenetic hallmark tightly linked to BAP1 loss and high-risk molecular class | High metastatic risk, poor prognosis, earlier dissemination | (iavarone2025ocularmelanomaa pages 4-6, kastelan2026precisiononcologyin pages 4-5, lamasfrancis2024impactofdriver pages 1-2, pasarica2024pathologicalandmolecular pages 9-10) |
| Progression | SF3B1 mutation (often R625) | ~15–25%; 20–25% in some reviews | Aberrant 3' splice-site usage / altered RNA splicing | Intermediate-risk group; characteristically associated with late-onset metastasis rather than early dissemination | (iavarone2025ocularmelanomaa pages 4-6, kastelan2026precisiononcologyin pages 4-5, dore2026clinicalmolecularpathology pages 3-5) |
| Progression | EIF1AX mutation | ~8–19%; 8–15% in some reviews | Translation initiation factor alteration; typically with disomy 3 | Low metastatic risk; favorable prognosis / excellent survival | (ambrosio2026amultifacetedapproach pages 9-12, kastelan2026precisiononcologyin pages 4-5, dore2026clinicalmolecularpathology pages 3-5) |
| Progression | 8q gain / amplification | ~40–55% | Copy-number gain that augments metastatic potential; may involve drivers in the 8q region | Adverse; often co-occurs with monosomy 3 and worsens metastatic risk | (kastelan2026precisiononcologyin pages 4-5, lamasfrancis2024impactofdriver pages 1-2, pasarica2024pathologicalandmolecular pages 9-10) |
| Progression / Protective | 6p gain / amplification | Not consistently quantified in provided evidence | Cytogenetic change associated with disomy 3 / class 1 biology | Favorable or relatively protective prognostic association | (ambrosio2026amultifacetedapproach pages 9-12, iavarone2025ocularmelanomaa pages 4-6, lamasfrancis2024impactofdriver pages 1-2, pasarica2024pathologicalandmolecular pages 9-10) |
| Prognostic biomarker | PRAME expression positive | ~29.9% PRAME+ in prospective COOG2 cohort | RNA expression biomarker that refines metastatic-risk stratification within GEP classes | Worse outcomes than PRAME-negative tumors; increases risk within both class 1 and class 2 tumors | (harbour202415geneexpressionprofile pages 5-6, harbour202415geneexpressionprofile pages 17-18, harbour202415geneexpressionprofile pages 1-2) |
| Prognostic classifier | TCGA group A | Not a frequency; 5-year distant metastasis rate 4% | Integrated chromosome 3/8q-based molecular subclass | Lowest-risk TCGA class | (pasarica2024pathologicalandmolecular pages 1-2, pasarica2024pathologicalandmolecular pages 9-10) |
| Prognostic classifier | TCGA group B | Not a frequency; 5-year distant metastasis rate 20% | Integrated chromosome 3/8q-based molecular subclass | Low-intermediate risk | (pasarica2024pathologicalandmolecular pages 1-2, pasarica2024pathologicalandmolecular pages 9-10) |
| Prognostic classifier | TCGA group C | Not a frequency; 5-year distant metastasis rate 33% | Integrated chromosome 3/8q-based molecular subclass | Intermediate-high risk | (pasarica2024pathologicalandmolecular pages 1-2, pasarica2024pathologicalandmolecular pages 9-10) |
| Prognostic classifier | TCGA group D | Not a frequency; 5-year distant metastasis rate 63% | Integrated chromosome 3/8q-based molecular subclass | Highest-risk TCGA class | (pasarica2024pathologicalandmolecular pages 1-2, pasarica2024pathologicalandmolecular pages 9-10) |
Table: This table summarizes the main initiating drivers, secondary prognostic alterations, and molecular classifiers in uveal melanoma. It is useful for quickly linking each alteration to approximate frequency, biology, and metastatic-risk implications.
A large prospective multi-center study (COOG2; n=1,577) validated integration of a 15-gene expression profile (15-GEP) with PRAME RNA expression for prognostic stratification, and concluded the integrated classifier supports “risk-adjusted metastatic surveillance and adjuvant trial stratification”. (harbour202415geneexpressionprofile pages 1-2)
Quantitatively, 5-year metastasis-free survival (MFS) differed strongly by integrated status: - Class 1/PRAME−: 95.6% - Class 1/PRAME+: 80.6% - Class 2/PRAME−: 58.3% - Class 2/PRAME+: 44.8% (harbour202415geneexpressionprofile pages 1-2)
A Kaplan–Meier visualization of these strata is available in the retrieved figure region. (harbour202415geneexpressionprofile media 9fd22c19)
Inferred from molecular subclassification, monosomy 3 and BAP1 aberrancy are associated with a distinct methylation pattern and dedifferentiation/metastatic phenotype. (pasarica2024pathologicalandmolecular pages 9-10, iavarone2025ocularmelanomaa pages 4-6)
A consensus mechanistic chain supported by the retrieved evidence is: 1) Initiation via constitutively active Gαq/Gα11 signaling (GNAQ/GNA11; or PLCB4/CYSLTR2), activating PKC/MAPK and YAP/TAZ programs → 2) Progression via acquisition of high-risk chromosomal changes (monosomy 3; 8q gain) and tumor suppressor loss (BAP1) or splicing alterations (SF3B1) → 3) Metastatic competence with strong liver tropism and poor survival once metastasis occurs. (iavarone2025ocularmelanomaa pages 4-6, kastelan2026precisiononcologyin pages 4-5, pasarica2024pathologicalandmolecular pages 1-2)
These suggestions are consistent with the mechanisms described in the cited sources: - GO: MAPK cascade; PI3K/AKT signaling; Hippo signaling / YAP/TAZ-mediated transcription; RNA splicing (SF3B1); chromatin organization (BAP1). (iavarone2025ocularmelanomaa pages 4-6, dore2026clinicalmolecularpathology pages 3-5) - CL: melanocyte (tumor cell-of-origin; uveal melanocytes). (pasarica2024pathologicalandmolecular pages 1-2)
A contemporary prospective uveal melanoma cohort (COOG2) used multimodal ophthalmic evaluation including fundus photography, OCT, and ocular ultrasonography, and staged tumors using AJCC 8th edition; baseline systemic staging commonly included CT chest/abdomen/pelvis, and surveillance emphasized liver imaging. (harbour202415geneexpressionprofile pages 2-4)
A 2024 plaque brachytherapy cohort reported UM diagnostic modalities including A-scan and B-scan echography, fluorescein angiography, indocyanine green angiography, OCT, and MRI, with AJCC 8th edition staging. (laliscia2024iodineplaquebrachytherapy pages 1-2)
AJCC 8th edition organizes T category by largest basal diameter and tumor thickness, with subclassifications for ciliary body involvement and extraocular extension; higher stage correlates with higher metastatic risk (e.g., Stage II ~3.1× and Stage III ~9.3× metastasis risk versus Stage I in one validation). (pasarica2024pathologicalandmolecular pages 2-4)
Differential diagnosis (“pseudomelanomas”) is widely recognized in the clinical literature but specific differential lists and distinguishing features were not directly retrievable from the 2023–2024 focused evidence pulled here.
United States (SEER 1975–2020 update). Mean age-adjusted incidence: 5.6 per million (95% CI 5.5–5.7), with higher incidence in males (6.3/million) than females (5.0/million), median age 63 years, and heavy predominance in White patients (~98%). Incidence overall was stable, with a small annual increase (APC 0.5%) in White patients. (weinberger2025uvealmelanoma5year pages 2-4)
Hungary nationwide (NHIF 2012–2021). Age-standardized incidence ranged 6.40–10.96 per 1,000,000 person-years; anatomic distribution was mostly choroidal (90%); all-cause mortality declined during 2012–2021 but could not be attributed clearly to improved treatments. (toth2024incidenceandmortality pages 1-2)
Primary treatment pattern shifts without survival improvement (US SEER). Surgery-alone decreased from 93% (1975–1977) to 21% (2017–2020), while radiation increased from 1% to 58%, but 5-year relative survival remained unchanged at ~82.8% (1975–2016). (weinberger2025uvealmelanoma5year pages 1-2)
Metastatic prognosis. In a SEER-linked analysis (2000–2019), mortality after metastatic uveal melanoma was reported as 80% by 1 year and 92% by 2 years. (arockiaraj2024ambientultravioletradiation pages 1-2)
Plaque brachytherapy and proton/charged-particle radiotherapy are the main globe-sparing modalities, with enucleation reserved for select cases (e.g., very large tumors, unfavorable location, or complications). Candidate selection is often driven by tumor size and proximity to critical structures such as the optic nerve. (semeniuk2024currentandemerging pages 2-3)
Plaque brachytherapy outcomes (2024 series). A 2024 125I plaque brachytherapy cohort (n=50) reported 5-year outcomes: local control 83.0%, metastasis-free survival 90.3%, overall survival 92.1%; radiation retinopathy grade 1–3 occurred in 18%. (laliscia2024iodineplaquebrachytherapy pages 1-2)
Radiotherapy complications (2024 review synthesis). A 2024 review summarized commonly reported complications after plaque brachytherapy including cataracts (~20%), radiation maculopathy (~25%), vitreous hemorrhage (~18%), retinal detachment (~2%), and secondary glaucoma (~23%). (semeniuk2024currentandemerging pages 2-3)
Charged-particle therapy vs brachytherapy (2024 meta-analysis). Charged-particle therapy had lower local recurrence than brachytherapy (OR 0.38, 95% CI 0.24–0.60), with no statistically significant differences in mortality, enucleation, or cataract; secondary glaucoma risk may be higher with charged-particle therapy. (tseng2024comparingefficacyof pages 1-2)
Proton therapy outcomes (2024–2025 evidence). - A 2024 proton therapy review described a large cohort with 10-year local control 92.1%, metastasis-free survival 76.4%, overall survival 64.1%, and eye retention 87.3%. (chan2024protontherapyin pages 6-7) - A 2025 systematic review/meta-analysis of proton therapy for choroidal melanoma reported local control 88% at 10 years and overall survival 39% at 10 years, with common complications including glaucoma (~17.9–27%), optic neuropathy (~12.8–64%), and cataracts (~29.6–39.8%). (miao2025efficacyandsafety pages 1-2)
Tebentafusp (TCR-bispecific gp100×CD3; ImmTAC). Tebentafusp is the first systemic therapy in UM with demonstrated overall survival benefit in a molecularly defined group (HLA-A02:01-positive). Pivotal-trial-level summaries report median OS 21.6 vs 16.9 months* (HR 0.68). (saldanha2025howwetreat pages 1-2)
ctDNA-guided response/prognosis with tebentafusp (2024). In a prospective cohort of 69 metastatic UM patients treated with tebentafusp, baseline detectable ctDNA was strongly prognostic (median OS 12.9 vs 40.5 months for detectable vs undetectable), and a ≥90% ctDNA reduction at 12 weeks correlated with longer OS (median 21.2 vs 12.9 months). (rodrigues2024prospectiveassessmentof pages 1-2)
Long-term tebentafusp follow-up (2024). A phase 1/2 long-term follow-up (median follow-up 48.5 months) reported median OS 17.4 months, with OS rates 62% (1-year), 40% (2-year), 23% (3-year), 14% (4-year); ctDNA clearance associated with markedly improved survival. (sacco2024longtermsurvivalfollowup pages 1-2)
Structured therapy summary artifact.
| Modality | Setting | Key outcomes/statistics | Key adverse events | Implementation notes | Primary sources (URLs; publication month/year) | Citation IDs |
|---|---|---|---|---|---|---|
| Tebentafusp | Unresectable/metastatic UM; HLA-A*02:01-positive adults | Phase 3 IMCgp100-202: median OS 21.6 vs 16.9 months, HR 0.68; 6-month PFS 31% vs 19%; ORR about 9%. Prospective 2024 ctDNA cohort: median PFS 2.8 months, median OS 21.8 months, ORR 10%. Meta-analysis: pooled 1-year OS 69%, 2-year OS 42%, 3-year OS 26%; pooled median PFS 2.74 months, pooled median OS 19.78 months. ctDNA: baseline detectable ctDNA associated with shorter OS (12.9 vs 40.5 months); ≥90% ctDNA reduction at 12 weeks associated with longer OS (21.2 vs 12.9 months); ctDNA clearance in earlier long-term study associated with 100% 1-year, 73% 2-year, 45% 3-year OS | CRS very common: 89% in review of pivotal data; pooled CRS 86% in meta-analysis. Other common AEs: rash 85%, pyrexia 79%, pruritus 72%, hypotension 43%; grade 3/4 TRAEs 44% in phase 3-style data; pooled grade ≥3 TRAEs 40% | First systemic therapy with demonstrated OS benefit in mUM; restricted to HLA-A*02:01 (~45–50% eligible). Step-up dosing and monitoring required during first infusions due to CRS. Radiographic response may underestimate benefit; ctDNA is promising but still investigational | Saldanha et al., ESMO Open https://doi.org/10.1016/j.esmoop.2025.104496 (Apr 2025); Rodrigues et al., Nature Communications https://doi.org/10.1038/s41467-024-53145-0 (Oct 2024); Sacco et al., J Immunother Cancer https://doi.org/10.1136/jitc-2024-009028 (Jun 2024); Wang et al., Front Oncol https://doi.org/10.3389/fonc.2025.1667282 (Oct 2025) | (saldanha2025howwetreat pages 1-2, rodrigues2024prospectiveassessmentof pages 1-2, sacco2024longtermsurvivalfollowup pages 1-2, wang2025evaluatingtheefficacy pages 1-2, wang2025evaluatingtheefficacy pages 7-10) |
| Ipilimumab + nivolumab | Advanced/metastatic UM, typically HLA-unrestricted | Current corpus contains only limited higher-level comparative evidence. A 2025 retrospective real-world series outside the cited context reported ORR 21%, median PFS 5.8 months, median OS 12.3 months, but this item is not available as a citable context ID here. Within current citable corpus, reviews state dual ICI has some activity but substantially less robust evidence than tebentafusp and no randomized OS advantage established in the provided evidence | Immune-related toxicity can be substantial; specific citable rates not robustly available in current context for this regimen alone | For this artifact, note evidence gap in current citable corpus; tebentafusp remains preferred for eligible HLA-A*02:01-positive patients, while dual ICI is often considered for others in practice | Maurer et al., Clin Exp Med https://doi.org/10.1007/s10238-024-01497-8 (Oct 2024); Saldanha et al., ESMO Open https://doi.org/10.1016/j.esmoop.2025.104496 (Apr 2025) | (saldanha2025howwetreat pages 1-2) |
| Liver-directed percutaneous therapies (radioembolization, TACE, immunoembolization, percutaneous hepatic perfusion, thermal therapies) | Metastatic UM with liver-dominant disease | Systematic review of 26 studies / 955 patients: median OS 16 months, median PFS 8.2 months, median ORR 39% | Predominantly hematologic and gastrointestinal adverse events after percutaneous hepatic procedures | Important because liver is the dominant metastatic site in UM; used especially for liver-predominant disease and often combined with systemic strategies in practice | Inì et al., Technology in Cancer Research & Treatment https://doi.org/10.1177/15330338251343144 (May 2025) | (arockiaraj2024ambientultravioletradiation pages 1-2) |
| Tebentafusp + ctDNA monitoring | Metastatic UM on tebentafusp | ddPCR feasible in most patients: 97% had a trackable mutation; ctDNA detectable at baseline in ~61%. Strong prognostic/predictive signal for baseline detectability and early reduction | Biomarker study; safety details not primary endpoint in provided excerpt | Useful implementation adjunct for response/prognosis assessment, but not yet standard-of-care validated | Rodrigues et al., Nature Communications https://doi.org/10.1038/s41467-024-53145-0 (Oct 2024) | (rodrigues2024prospectiveassessmentof pages 1-2) |
| NCT06246149 – Adjuvant tebentafusp in high-risk ocular melanoma | Adjuvant / high-risk ocular melanoma after local therapy | Phase 3; recruiting; planned enrollment 290 | Not yet reported | Important ongoing study testing earlier use of tebentafusp beyond overt metastatic disease | ClinicalTrials.gov NCT06246149 (recruiting) | (saldanha2025howwetreat pages 1-2) |
| NCT07063875 – Tebentafusp + IL-2 | Metastatic UM combination immunotherapy | Phase 1/2; recruiting; planned enrollment 8 | Not yet reported | Exploratory combination intended to intensify immune activation/T-cell persistence | ClinicalTrials.gov NCT07063875 (recruiting) | (NCT07063875 chunk 1) |
| NCT06070012 – First-line tebentafusp in HLA-A*02:01-positive previously untreated mUM | First-line metastatic UM | Phase 2; recruiting; planned enrollment 44 | Not yet reported | Focuses on untreated HLA-A*02:01-positive metastatic disease and may refine biomarker use | ClinicalTrials.gov NCT06070012 (recruiting) | (saldanha2025howwetreat pages 1-2) |
| NCT06627244 – Tebentafusp + radioembolization | Metastatic UM with liver-directed combination strategy | Phase 2; recruiting; planned enrollment 30 | Not yet reported | Directly tests systemic tebentafusp plus liver-directed radiation embolization | ClinicalTrials.gov NCT06627244 (recruiting) | (saldanha2025howwetreat pages 1-2) |
| NCT06626516 – Tebentafusp with liver-directed therapy (LDT) | Metastatic UM | Phase 1/2; recruiting; planned enrollment 109 | Not yet reported | Broader platform for combining tebentafusp with liver-directed treatment | ClinicalTrials.gov NCT06626516 (recruiting) | (saldanha2025howwetreat pages 1-2) |
| NCT07276386 – Melphalan/HDS via PHP + tebentafusp | Metastatic UM | Phase 2; recruiting; planned enrollment 18 | Not yet reported | Evaluates tebentafusp with percutaneous hepatic perfusion/melphalan strategy | ClinicalTrials.gov NCT07276386 (recruiting) | (saldanha2025howwetreat pages 1-2) |
Table: This table summarizes the main systemic and liver-directed treatment options for metastatic uveal melanoma, with emphasis on tebentafusp outcomes, biomarker data, and ongoing combination/adjuvant trials. It is useful for quickly comparing efficacy, toxicity, and real-world implementation constraints such as HLA restriction and liver-dominant disease management.
These MAXO suggestions are provided for KB normalization (names provided; ontology IDs not available in corpus): - Plaque brachytherapy (episcleral plaque radiotherapy) (laliscia2024iodineplaquebrachytherapy pages 1-2) - Proton beam therapy (charged-particle radiotherapy) (miao2025efficacyandsafety pages 1-2) - Enucleation (eye removal surgery) (referenced as comparator in reviews) (semeniuk2024currentandemerging pages 2-3) - Tebentafusp therapy (bispecific T-cell engager / TCR-bispecific) (rodrigues2024prospectiveassessmentof pages 1-2) - Liver-directed embolization/perfusion/ablation (interventional radiology) (arockiaraj2024ambientultravioletradiation pages 1-2)
No validated primary-prevention interventions (analogous to vaccines) exist for UM in the current evidence corpus. Risk reduction is generally limited by the uncertain/heterogeneous role of UVR, especially for posterior UM. (arockiaraj2024ambientultravioletradiation pages 1-2)
Risk-adapted surveillance using molecular prognostics (2023 expert review). A Nature Reviews Clinical Oncology review recommends surveillance stratified by molecular risk (GEP class and PRAME): e.g., annual imaging for low risk, 6–12 month imaging for intermediate risk, and 3–6 month imaging for high risk early after treatment, with continued surveillance given potential for late metastases. (carvajal2023advancesinthe pages 5-7)
Delphi expert consensus (2025; surveys conducted 2024–2025). A multidisciplinary Delphi panel produced consensus surveillance guidance for intermediate- and high-risk UM, favoring contrast-enhanced hepatic imaging (CT/MRI) over ultrasound and not recommending PET/CT for routine surveillance. It also proposed specific surveillance frequencies (e.g., intermediate risk at least every 3–6 months for 5 years, then annually to ≥10 years; high risk every 3–6 months in years 1–5 and every 6–12 months in years 6–10, with consideration beyond 10 years). (alban2025metastaticuvealmelanoma pages 7-9, alban2025metastaticuvealmelanoma pages 5-7)
While detailed veterinary natural-disease epidemiology was not retrieved, the UM research ecosystem includes diverse model systems. A 2026 Cancer Research paper reports development of an immune-competent genetically engineered mouse model incorporating stepwise alterations (GNAQ Q209L expression, BAP1 deletion, MYC activation) that produces intraocular tumors and recapitulates features of aggressive class 2 UM, including immunosuppressive macrophage populations and exhausted T cells (supporting immunotherapy research). (paduszynska2024comprehensiveinsightsinto pages 11-13)
1) Prospective validation of integrated prognostic biomarkers (15-GEP + PRAME) at multi-center scale (COOG2; published Oct 2024) enabling risk-adjusted surveillance and trial stratification. (harbour202415geneexpressionprofile pages 1-2, harbour202415geneexpressionprofile media 9fd22c19) 2) Prospective ctDNA monitoring during tebentafusp therapy (published Oct 2024) showing strong prognostic and predictive utility of ctDNA detectability and early reduction. (rodrigues2024prospectiveassessmentof pages 1-2) 3) Radiotherapy comparative evidence synthesis (Apr 2024; Oct 2024) refining when proton/charged-particle therapy may reduce local recurrence compared with plaque brachytherapy, while highlighting uncertainty in survival differences and complication tradeoffs. (tseng2024comparingefficacyof pages 1-2, semeniuk2024currentandemerging pages 2-3) 4) Large registry-based UVR analysis (Feb 2024) supporting the view that UVR risk is subsite-dependent (ciliary body/iris vs choroid), rather than uniformly causal across UM. (arockiaraj2024ambientultravioletradiation pages 1-2)
References
(pasarica2024pathologicalandmolecular pages 1-2): Mihai Adrian Păsărică, Paul Filip Curcă, Christiana Diana Maria Dragosloveanu, Alexandru Călin Grigorescu, and Cosmin Ionuț Nisipașu. Pathological and molecular diagnosis of uveal melanoma. Diagnostics, 14:958, May 2024. URL: https://doi.org/10.3390/diagnostics14090958, doi:10.3390/diagnostics14090958. This article has 11 citations.
(NCT07063875 chunk 1): Anthony Joshua, FRACP. Adding IL-2 to Tebentafusp to Eradicate Cancer Progression. St Vincent's Hospital, Sydney. 2025. ClinicalTrials.gov Identifier: NCT07063875
(weinberger2025uvealmelanoma5year pages 1-2): Yehonatan Weinberger, James Bena, and Arun D. Singh. Uveal melanoma: 5-year update on incidence, treatment, and survival (seer 1975–2020). Ocular Oncology and Pathology, 11:30-36, Dec 2025. URL: https://doi.org/10.1159/000543151, doi:10.1159/000543151. This article has 12 citations and is from a peer-reviewed journal.
(pasarica2024pathologicalandmolecular pages 2-4): Mihai Adrian Păsărică, Paul Filip Curcă, Christiana Diana Maria Dragosloveanu, Alexandru Călin Grigorescu, and Cosmin Ionuț Nisipașu. Pathological and molecular diagnosis of uveal melanoma. Diagnostics, 14:958, May 2024. URL: https://doi.org/10.3390/diagnostics14090958, doi:10.3390/diagnostics14090958. This article has 11 citations.
(lissak2024whatsetsuveal pages 1-3): Karina Lissak, Zuzanna Szczepaniak, Agata Konopka, Natalia Wdowiak, Martyna Choinka, Małgorzata Komarów, Dominika Karasińska, Jakub Kalisiak, Mateusz Koralewicz, Milena Orzeł, and Bartłomiej Orzeł. What sets uveal melanoma apart, and how can we address it? a comprehensive review of pathophysiology, diagnosis and treatment. Quality in Sport, 23:55123, Sep 2024. URL: https://doi.org/10.12775/qs.2024.23.55123, doi:10.12775/qs.2024.23.55123. This article has 1 citations.
(weinberger2025uvealmelanoma5year pages 2-4): Yehonatan Weinberger, James Bena, and Arun D. Singh. Uveal melanoma: 5-year update on incidence, treatment, and survival (seer 1975–2020). Ocular Oncology and Pathology, 11:30-36, Dec 2025. URL: https://doi.org/10.1159/000543151, doi:10.1159/000543151. This article has 12 citations and is from a peer-reviewed journal.
(toth2024incidenceandmortality pages 1-2): Gábor Tóth, Béla Muzsik, Attila Szajkó, Pál Kerber, Elek Dinya, Béla Csákány, Zoltán Zsolt Nagy, and János Németh. Incidence and mortality of uveal melanoma in hungary: a nationwide study. Cancers, 16:931, Feb 2024. URL: https://doi.org/10.3390/cancers16050931, doi:10.3390/cancers16050931. This article has 5 citations.
(iavarone2025ocularmelanomaa pages 4-6): Lucia Iavarone, Renato Franco, Federica Zito Marino, Giuseppe D’Abbronzo, Giuseppe Argenziano, Camila Scharf, Grazia Nucci, Andrea Ronchi, and Gerardo Cazzato. Ocular melanoma: a comprehensive review with a focus on molecular biology. International Journal of Molecular Sciences, 26:9799, Oct 2025. URL: https://doi.org/10.3390/ijms26199799, doi:10.3390/ijms26199799. This article has 6 citations.
(jager2020uvealmelanoma pages 2-3): Martine J. Jager, C. L. Shields, Colleen M. Cebulla, Mohamed H. Abdel-Rahman, Hans E. Grossniklaus, Marc-Henri Stern, Richard D. Carvajal, Rubens N. Belfort, Renbing Jia, J. A. Shields, and B. Damato. Uveal melanoma. Nature Reviews Disease Primers, 6:1-25, Apr 2020. URL: https://doi.org/10.1038/s41572-020-0158-0, doi:10.1038/s41572-020-0158-0. This article has 954 citations.
(arockiaraj2024ambientultravioletradiation pages 1-2): Basilica M. Arockiaraj, Elizabeth K. Cahoon, Michael R. Sargen, Erping Long, Margaret A. Tucker, and Jim Z. Mai. Ambient ultraviolet radiation and ocular melanoma incidence in the united states, 2000−2019. Eye, 38:1618-1625, Feb 2024. URL: https://doi.org/10.1038/s41433-024-02959-9, doi:10.1038/s41433-024-02959-9. This article has 14 citations and is from a peer-reviewed journal.
(repo2025germlinecancersusceptibility pages 1-3): P. Repo, Eveliina Jakkula, Juho Hiltunen, Heidi Putkuri, Aleksandra Staskiewicz‐Tuikkanen, Reetta‐Stiina Järvinen, M. Täll, V. Raivio, Ranaa Al-Jamal, T. Kivelä, and J. Turunen. Germline cancer susceptibility variants in patients with uveal melanoma. Pigment Cell & Melanoma Research, Aug 2025. URL: https://doi.org/10.1111/pcmr.70041, doi:10.1111/pcmr.70041. This article has 0 citations and is from a domain leading peer-reviewed journal.
(wadt2024characterizationofsomatic pages 1-2): Karin A. W. Wadt, Katja Harbst, Mette M. B. Sjøl, Frida Rosengren, Christina Westmose Yde, Kristoffer Staal Rohrberg, Marlene Richter Jensen, Steffen Heegaard, Jens Folke Kiilgaard, Anne-Marie Gerdes, Nicholas Hayward, and Göran B. Jönsson. Characterization of somatic mutations in sporadic uveal melanoma and uveal melanoma in patients with germline bap1 pathogenic variants. PLOS ONE, 19:e0306386, Oct 2024. URL: https://doi.org/10.1371/journal.pone.0306386, doi:10.1371/journal.pone.0306386. This article has 1 citations and is from a peer-reviewed journal.
(fili2021presentingsymptomsare pages 1-2): Maria Fili, Stefan Seregard, and Gustav Stålhammar. Presenting symptoms are associated with uveal melanoma-related death. Ophthalmology, 128:1107-1109, Jul 2021. URL: https://doi.org/10.1016/j.ophtha.2020.11.023, doi:10.1016/j.ophtha.2020.11.023. This article has 11 citations and is from a highest quality peer-reviewed journal.
(sabazade2022vasculogenicmimicrycorrelates pages 1-3): Shiva Sabazade, Viktor Gill, Christina Herrspiegel, and Gustav Stålhammar. Vasculogenic mimicry correlates to presenting symptoms and mortality in uveal melanoma. Journal of Cancer Research and Clinical Oncology, 148:587-597, Nov 2022. URL: https://doi.org/10.1007/s00432-021-03851-9, doi:10.1007/s00432-021-03851-9. This article has 20 citations and is from a peer-reviewed journal.
(kaliki2017uvealmelanomarelatively pages 4-6): S Kaliki and C L Shields. Uveal melanoma: relatively rare but deadly cancer. Eye, 31:241-257, Feb 2017. URL: https://doi.org/10.1038/eye.2016.275, doi:10.1038/eye.2016.275. This article has 877 citations and is from a peer-reviewed journal.
(semeniuk2024currentandemerging pages 2-3): Oleksii Semeniuk, Esther Yu, and Mark J. Rivard. Current and emerging radiotherapy options for uveal melanoma. Cancers, 16:1074, Mar 2024. URL: https://doi.org/10.3390/cancers16051074, doi:10.3390/cancers16051074. This article has 14 citations.
(pasarica2024pathologicalandmolecular pages 9-10): Mihai Adrian Păsărică, Paul Filip Curcă, Christiana Diana Maria Dragosloveanu, Alexandru Călin Grigorescu, and Cosmin Ionuț Nisipașu. Pathological and molecular diagnosis of uveal melanoma. Diagnostics, 14:958, May 2024. URL: https://doi.org/10.3390/diagnostics14090958, doi:10.3390/diagnostics14090958. This article has 11 citations.
(ambrosio2026amultifacetedapproach pages 9-12): M Ambrosio. A multi-faceted approach to uncover novel vulnerabilities in uveal melanoma: from etiology to the identification of prognostic biomarkers. Unknown journal, 2026.
(kastelan2026precisiononcologyin pages 4-5): Snježana Kaštelan, Fanka Gilevska, Zora Tomić, Josipa Živko, and Tamara Nikuševa-Martić. Precision oncology in ocular melanoma: integrating molecular and liquid biopsy biomarkers. Current Issues in Molecular Biology, 48:131, Jan 2026. URL: https://doi.org/10.3390/cimb48020131, doi:10.3390/cimb48020131. This article has 0 citations.
(dore2026clinicalmolecularpathology pages 3-5): Stefano Dore, Matteo Sacchi, Antonio Pinna, Giuseppe Palmieri, and Panagiotis Paliogiannis. Clinical molecular pathology and treatment developments in advanced uveal melanoma: state of the art. Oncology Research, Jan 2026. URL: https://doi.org/10.32604/or.2025.071831, doi:10.32604/or.2025.071831. This article has 0 citations and is from a peer-reviewed journal.
(lamasfrancis2024impactofdriver pages 1-2): David Lamas-Francis, Carmen Antía Rodríguez-Fernández, Elia de Esteban-Maciñeira, Paula Silva-Rodríguez, María Pardo, Manuel Bande-Rodríguez, and María José Blanco-Teijeiro. Impact of driver mutations on metastasis-free survival in uveal melanoma: a meta-analysis. Cancers, 16:2510, Jul 2024. URL: https://doi.org/10.3390/cancers16142510, doi:10.3390/cancers16142510. This article has 4 citations.
(harbour202415geneexpressionprofile pages 5-6): J. William Harbour, Zelia M. Correa, Amy C. Schefler, Prithvi Mruthyunjaya, Miguel A. Materin, Thomas A. Aaberg, Alison H. Skalet, David A. Reichstein, Ezekiel Weis, Ivana K. Kim, Timothy S. Fuller, Hakan Demirci, Kisha D. Piggott, Basil K. Williams, Eugene Shildkrot, Antonio Capone, Scott C. Oliver, Scott D. Walter, John Mason, Devron H. Char, Michael Altaweel, Jill R. Wells, Jay S. Duker, Peter G. Hovland, Dan S. Gombos, Tony Tsai, Cameron Javid, Brian P. Marr, Ang Gao, Christina L. Decatur, James J. Dollar, Stefan Kurtenbach, and Song Zhang. 15-gene expression profile and prame as integrated prognostic test for uveal melanoma: first report of collaborative ocular oncology group study no. 2 (coog2.1). Journal of Clinical Oncology, 42:3319-3329, Oct 2024. URL: https://doi.org/10.1200/jco.24.00447, doi:10.1200/jco.24.00447. This article has 52 citations and is from a highest quality peer-reviewed journal.
(harbour202415geneexpressionprofile pages 17-18): J. William Harbour, Zelia M. Correa, Amy C. Schefler, Prithvi Mruthyunjaya, Miguel A. Materin, Thomas A. Aaberg, Alison H. Skalet, David A. Reichstein, Ezekiel Weis, Ivana K. Kim, Timothy S. Fuller, Hakan Demirci, Kisha D. Piggott, Basil K. Williams, Eugene Shildkrot, Antonio Capone, Scott C. Oliver, Scott D. Walter, John Mason, Devron H. Char, Michael Altaweel, Jill R. Wells, Jay S. Duker, Peter G. Hovland, Dan S. Gombos, Tony Tsai, Cameron Javid, Brian P. Marr, Ang Gao, Christina L. Decatur, James J. Dollar, Stefan Kurtenbach, and Song Zhang. 15-gene expression profile and prame as integrated prognostic test for uveal melanoma: first report of collaborative ocular oncology group study no. 2 (coog2.1). Journal of Clinical Oncology, 42:3319-3329, Oct 2024. URL: https://doi.org/10.1200/jco.24.00447, doi:10.1200/jco.24.00447. This article has 52 citations and is from a highest quality peer-reviewed journal.
(harbour202415geneexpressionprofile pages 1-2): J. William Harbour, Zelia M. Correa, Amy C. Schefler, Prithvi Mruthyunjaya, Miguel A. Materin, Thomas A. Aaberg, Alison H. Skalet, David A. Reichstein, Ezekiel Weis, Ivana K. Kim, Timothy S. Fuller, Hakan Demirci, Kisha D. Piggott, Basil K. Williams, Eugene Shildkrot, Antonio Capone, Scott C. Oliver, Scott D. Walter, John Mason, Devron H. Char, Michael Altaweel, Jill R. Wells, Jay S. Duker, Peter G. Hovland, Dan S. Gombos, Tony Tsai, Cameron Javid, Brian P. Marr, Ang Gao, Christina L. Decatur, James J. Dollar, Stefan Kurtenbach, and Song Zhang. 15-gene expression profile and prame as integrated prognostic test for uveal melanoma: first report of collaborative ocular oncology group study no. 2 (coog2.1). Journal of Clinical Oncology, 42:3319-3329, Oct 2024. URL: https://doi.org/10.1200/jco.24.00447, doi:10.1200/jco.24.00447. This article has 52 citations and is from a highest quality peer-reviewed journal.
(harbour202415geneexpressionprofile media 9fd22c19): J. William Harbour, Zelia M. Correa, Amy C. Schefler, Prithvi Mruthyunjaya, Miguel A. Materin, Thomas A. Aaberg, Alison H. Skalet, David A. Reichstein, Ezekiel Weis, Ivana K. Kim, Timothy S. Fuller, Hakan Demirci, Kisha D. Piggott, Basil K. Williams, Eugene Shildkrot, Antonio Capone, Scott C. Oliver, Scott D. Walter, John Mason, Devron H. Char, Michael Altaweel, Jill R. Wells, Jay S. Duker, Peter G. Hovland, Dan S. Gombos, Tony Tsai, Cameron Javid, Brian P. Marr, Ang Gao, Christina L. Decatur, James J. Dollar, Stefan Kurtenbach, and Song Zhang. 15-gene expression profile and prame as integrated prognostic test for uveal melanoma: first report of collaborative ocular oncology group study no. 2 (coog2.1). Journal of Clinical Oncology, 42:3319-3329, Oct 2024. URL: https://doi.org/10.1200/jco.24.00447, doi:10.1200/jco.24.00447. This article has 52 citations and is from a highest quality peer-reviewed journal.
(harbour202415geneexpressionprofile pages 2-4): J. William Harbour, Zelia M. Correa, Amy C. Schefler, Prithvi Mruthyunjaya, Miguel A. Materin, Thomas A. Aaberg, Alison H. Skalet, David A. Reichstein, Ezekiel Weis, Ivana K. Kim, Timothy S. Fuller, Hakan Demirci, Kisha D. Piggott, Basil K. Williams, Eugene Shildkrot, Antonio Capone, Scott C. Oliver, Scott D. Walter, John Mason, Devron H. Char, Michael Altaweel, Jill R. Wells, Jay S. Duker, Peter G. Hovland, Dan S. Gombos, Tony Tsai, Cameron Javid, Brian P. Marr, Ang Gao, Christina L. Decatur, James J. Dollar, Stefan Kurtenbach, and Song Zhang. 15-gene expression profile and prame as integrated prognostic test for uveal melanoma: first report of collaborative ocular oncology group study no. 2 (coog2.1). Journal of Clinical Oncology, 42:3319-3329, Oct 2024. URL: https://doi.org/10.1200/jco.24.00447, doi:10.1200/jco.24.00447. This article has 52 citations and is from a highest quality peer-reviewed journal.
(laliscia2024iodineplaquebrachytherapy pages 1-2): CONCETTA LALISCIA, FRANCO PERRONE, FEDERICA CRESTI, FRANCESCA GUIDO, TAIUSHA FUENTES, CECILIA TRIPPA, FABIOLA PAIAR, GUGLIELMO PELLEGRINI, and FEDERICA GENOVESI EBERT. Iodine plaque brachytherapy a customized conservative approach to the management of medium/large-sized uveal melanoma. In Vivo, 38:1814-1822, Jan 2024. URL: https://doi.org/10.21873/invivo.13633, doi:10.21873/invivo.13633. This article has 5 citations and is from a peer-reviewed journal.
(tseng2024comparingefficacyof pages 1-2): Yu-Hsuan Tseng, Chia-An Hsu, and Yu-Bai Chou. Comparing efficacy of charged-particle therapy with brachytherapy in treatment of uveal melanoma. Eye, 38:1882-1890, Apr 2024. URL: https://doi.org/10.1038/s41433-024-03035-y, doi:10.1038/s41433-024-03035-y. This article has 4 citations and is from a peer-reviewed journal.
(chan2024protontherapyin pages 6-7): Adrian Wai Chan, Haibo Lin, Irini Yacoub, Arpit M. Chhabra, J. Isabelle Choi, and Charles B. Simone. Proton therapy in uveal melanoma. Cancers, 16:3497, Oct 2024. URL: https://doi.org/10.3390/cancers16203497, doi:10.3390/cancers16203497. This article has 19 citations.
(miao2025efficacyandsafety pages 1-2): Yuxin Miao, Tingwei Zheng, Qiuning Zhang, Meixuan Li, Qihang Lei, Qin Liu, Hongtao Luo, and Huiling Bai. Efficacy and safety of proton radiotherapy in treating choroidal melanoma: a systematic review and meta-analysis. Radiation Oncology (London, England), Jan 2025. URL: https://doi.org/10.1186/s13014-024-02580-w, doi:10.1186/s13014-024-02580-w. This article has 7 citations.
(saldanha2025howwetreat pages 1-2): E.F. Saldanha, M.F. Ribeiro, I. Hirsch, A. Spreafico, S.D. Saibil, and M.O. Butler. How we treat patients with metastatic uveal melanoma. ESMO Open, 10:104496, Apr 2025. URL: https://doi.org/10.1016/j.esmoop.2025.104496, doi:10.1016/j.esmoop.2025.104496. This article has 12 citations and is from a domain leading peer-reviewed journal.
(rodrigues2024prospectiveassessmentof pages 1-2): Manuel Rodrigues, Toulsie Ramtohul, Aurore Rampanou, José Luis Sandoval, Alexandre Houy, Vincent Servois, Léah Mailly-Giacchetti, Gaelle Pierron, Anne Vincent-Salomon, Nathalie Cassoux, Pascale Mariani, Caroline Dutriaux, Marc Pracht, Thomas Ryckewaert, Jean-Emmanuel Kurtz, Sergio Roman-Roman, Sophie Piperno-Neumann, François-Clément Bidard, Marc-Henri Stern, and Shufang Renault. Prospective assessment of circulating tumor dna in patients with metastatic uveal melanoma treated with tebentafusp. Nature Communications, Oct 2024. URL: https://doi.org/10.1038/s41467-024-53145-0, doi:10.1038/s41467-024-53145-0. This article has 30 citations and is from a highest quality peer-reviewed journal.
(sacco2024longtermsurvivalfollowup pages 1-2): Joseph J Sacco, Richard D Carvajal, Marcus O Butler, Alexander N Shoushtari, Jessica C Hassel, Alexandra Ikeguchi, Leonel Hernandez-Aya, Paul Nathan, Omid Hamid, Josep M Piulats, Matthew Rioth, Douglas B Johnson, Jason J Luke, Enrique Espinosa, Serge Leyvraz, Laura Collins, Chris Holland, and Takami Sato. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. Journal for Immunotherapy of Cancer, 12:e009028, Jun 2024. URL: https://doi.org/10.1136/jitc-2024-009028, doi:10.1136/jitc-2024-009028. This article has 33 citations and is from a domain leading peer-reviewed journal.
(wang2025evaluatingtheefficacy pages 1-2): Yanlin Wang, Wen Sun, and Bing Wang. Evaluating the efficacy and safety of tebentafusp in the treatment of metastatic uveal melanoma: a 2025 update systematic review and meta-analysis. Frontiers in Oncology, Oct 2025. URL: https://doi.org/10.3389/fonc.2025.1667282, doi:10.3389/fonc.2025.1667282. This article has 4 citations.
(wang2025evaluatingtheefficacy pages 7-10): Yanlin Wang, Wen Sun, and Bing Wang. Evaluating the efficacy and safety of tebentafusp in the treatment of metastatic uveal melanoma: a 2025 update systematic review and meta-analysis. Frontiers in Oncology, Oct 2025. URL: https://doi.org/10.3389/fonc.2025.1667282, doi:10.3389/fonc.2025.1667282. This article has 4 citations.
(carvajal2023advancesinthe pages 5-7): Richard D. Carvajal, Joseph J. Sacco, Martine J. Jager, David J. Eschelman, Roger Olofsson Bagge, J. William Harbour, Nicholas D. Chieng, Sapna P. Patel, Anthony M. Joshua, and Sophie Piperno-Neumann. Advances in the clinical management of uveal melanoma. Nature Reviews Clinical Oncology, 20:99-115, Jan 2023. URL: https://doi.org/10.1038/s41571-022-00714-1, doi:10.1038/s41571-022-00714-1. This article has 267 citations and is from a domain leading peer-reviewed journal.
(alban2025metastaticuvealmelanoma pages 7-9): Juan Alban, R. Christopher Bowen, David A. Reichstein, Meredith McKean, Jose Lutzky, Ezekiel Weis, Richard D. Carvajal, Susan Dulka, Brian G. Morse, Marcus O. Butler, Suthee Rapisuwon, Kevin B. Kim, Sanjay Chandrasekaran, Allison Betof Warner, Jonathan S. Zager, Bartosz Chmielowski, Sapna P. Patel, Leonel Fernando Hernandez-Aya, Zelia M. Correa, Leslie A. Fecher, Yana G. Najjar, Kamaneh Montazeri, Alexander N. Shoushtari, Asad Javed, Dan S. Gombos, April K. S. Salama, Katy Tsai, Frank H. Miller, Nikhil Khushalani, Rino S. Seedor, Evan J. Lipson, Sunil A. Reddy, Elizabeth Buchbinder, Shailender Bhatia, Anna Pavlick, Inderjit Mehmi, Thomas Aaberg, Alexandra P. Ikeguchi, Ivana K. Kim, Scott D. Walter, Arun D. Singh, Ryan J. Sullivan, Jacob S. Choi, Basil K. Williams Jr., Marlana Orloff, Prithvi Mruthyunjaya, Megan D. Schollenberger, Namita Gandhi, J. William Harbour, and Sunandana Chandra. Metastatic uveal melanoma surveillance: a delphi panel consensus. Cancers, 18:121, Dec 2025. URL: https://doi.org/10.3390/cancers18010121, doi:10.3390/cancers18010121. This article has 0 citations.
(alban2025metastaticuvealmelanoma pages 5-7): Juan Alban, R. Christopher Bowen, David A. Reichstein, Meredith McKean, Jose Lutzky, Ezekiel Weis, Richard D. Carvajal, Susan Dulka, Brian G. Morse, Marcus O. Butler, Suthee Rapisuwon, Kevin B. Kim, Sanjay Chandrasekaran, Allison Betof Warner, Jonathan S. Zager, Bartosz Chmielowski, Sapna P. Patel, Leonel Fernando Hernandez-Aya, Zelia M. Correa, Leslie A. Fecher, Yana G. Najjar, Kamaneh Montazeri, Alexander N. Shoushtari, Asad Javed, Dan S. Gombos, April K. S. Salama, Katy Tsai, Frank H. Miller, Nikhil Khushalani, Rino S. Seedor, Evan J. Lipson, Sunil A. Reddy, Elizabeth Buchbinder, Shailender Bhatia, Anna Pavlick, Inderjit Mehmi, Thomas Aaberg, Alexandra P. Ikeguchi, Ivana K. Kim, Scott D. Walter, Arun D. Singh, Ryan J. Sullivan, Jacob S. Choi, Basil K. Williams Jr., Marlana Orloff, Prithvi Mruthyunjaya, Megan D. Schollenberger, Namita Gandhi, J. William Harbour, and Sunandana Chandra. Metastatic uveal melanoma surveillance: a delphi panel consensus. Cancers, 18:121, Dec 2025. URL: https://doi.org/10.3390/cancers18010121, doi:10.3390/cancers18010121. This article has 0 citations.
(paduszynska2024comprehensiveinsightsinto pages 11-13): N Paduszyńska, A Dąbrowska, and MJ Gonciarz. Comprehensive insights into uveal melanoma–risk factors, pathophysiology, prognosis, and diagnostic approaches. Unknown journal, 2024.